GlassScriptPhysician profile
Mohammed W Kabir
NPI 1861494122
$1,157.41
in general payments reported to CMS, 2019-2025
16 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $44.34 · 2021: $124 · 2022: $200 · 2023: $144 · 2024: $113 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $371.84 | 2025 | Breztri |
| Shield Therapeutics INC | $169.50 | 2022-2024 | Accrufer |
| Abbvie INC. | $150.87 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.25 | 2021-2023 | |
| Pfizer INC. | $56.06 | 2022-2024 | |
| Myovant Sciences INC. | $51.34 | 2021-2022 | |
| Exeltis, USA INC. | $47.17 | 2019-2020 | |
| Sage Therapeutics, LLC | $44.29 | 2023-2024 | |
| Mission Pharmacal Company | $38.15 | 2019 | |
| Therapeuticsmd, INC. | $34.73 | 2021 | |
| Hologic Sales and Service, LLC | $33.34 | 2023 | Aptima |
| Astellas Pharma US INC | $26.72 | 2024 | Veozah |
| Avion Pharmaceuticals | $16.05 | 2022 | |
| Allergan, INC. | $14.93 | 2019 | |
| Ascend Therapeutics US, LLC | $13.20 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Kabir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.